Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054405 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00054405: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00054405 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054405, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase I trial to compare the effectiveness of interleukin-12 with or without interleukin-2 in treating young patients who have refractory or recurrent neuroblastoma. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining interleukin-2 with interleukin-12 may kill more tumor cells.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054405
The ClinicalTrials.gov registry entry for NCT00054405 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00054405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054405 about?
NCT00054405 is a clinical study titled "Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma". Phase I trial to compare the effectiveness of interleukin-12 with or without interleukin-2 in treating young patients who have refractory or recurrent neuroblastoma. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining interleukin-2 wit...
What is the current status of trial NCT00054405?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00054405?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054405?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.